



Ekterly[®]
(sebetralstat) tablets 300 mg

Meet Cari, a real EKTERLY patient

Age 45 | HAE Type I

A devoted mom and physical therapist from Texas, she's spent much of her life balancing the demands of family, work, and a rare disease that once disrupted every milestone. Cari's story shows the power of treating early and finding confidence in an on-demand treatment that works for her—so she can focus on what matters most.

INDICATION

EKTERLY[®] (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

IMPORTANT SAFETY INFORMATION

Adverse reactions: The most commonly reported adverse reaction was headache.

Please see additional Important Safety Information throughout.
Please see full [Prescribing Information](#).

Medical history

DIAGNOSIS:

Type I HAE, 8 years old

FAMILY HISTORY:

Father (HAE)

CURRENT HAE TREATMENT:

- **Prophylactic:** Long-term preventive therapy
- **On-demand:** EKTERLY¹



Cari's HAE attack profile

Here are the key details of Cari's attacks:

Triggers

- Physical exertion
- Stress
- Travel fatigue
- Postpartum hormonal changes

Symptoms

- Abdominal swelling and pain
- Swelling in extremities (hands, elbows, forearms, knees)
- Nausea and vomiting during abdominal attacks

Frequency

- Before prophylaxis: up to 6 attacks per month
- After prophylaxis: ~1 attack every 3 months


Attack management

- Treats all recognized attacks
- Treats attacks immediately

Attack locations

Throughout her life, Cari's attacks have affected multiple areas of her body, often triggered by physical strain or hormonal shifts. Abdominal attacks were historically her most severe and disruptive.

Attack sites treated with EKTERLY



“ *The fear of the next attack never really leaves you. The night after giving birth to my son, I spent more time in the bathroom than with him in my arms.*”

**Please see additional Important Safety Information throughout.
Please see full Prescribing Information.**

EKTERLY is the **first and only oral treatment** that lets patients like Cari treat at attack recognition^{1,2}

Rapid time to beginning of symptom relief with EKTERLY^{1,3,*}

PRIMARY ENDPOINT:


Median time to the beginning of symptom relief



Based on prespecifying that attacks with incomplete data were censored at timepoint zero. Analysis included in label assigns these attacks a value of 12 hours, resulting in a median of 2.0 hours.^{1,3}

EKTERLY enables rapid treatment within minutes of recognizing an attack³

MEDIAN TIME TO TREATMENT FROM ATTACK ONSET^{3,4}



One-dose symptom relief

96% of attacks that reached the primary endpoint achieved symptom relief with only 1 dose⁵

“

“Within 2 hours of taking EKTERLY, I started to feel some relief...By the 4-hour mark, I felt a lot better.”

Safety events with EKTERLY were similar to placebo¹

¹KONFIDENT was a multinational, randomized, double-blind, placebo-controlled, phase 3, crossover study of 136 patients from 17 countries. Study participants were randomized to receive either placebo, EKTERLY 300 mg, or EKTERLY 600 mg to treat 3 attacks in a 3-way crossover design using 1 of 6 treatment sequences. The primary endpoint was time to the beginning of symptom relief according to the 7-point Patient Global Impression of Change scale.^{3,5}

[†]KONFIDENT-S is a multicenter, open-label extension trial of 134 adult and adolescent (≥12 years of age) patients. Study participants had a confirmed diagnosis of HAE and ≥2 attacks within 3 months and were enrolled after completing the KONFIDENT phase 3 trial or de novo.⁵

IMPORTANT SAFETY INFORMATION

Drug interactions: EKTERLY is a substrate of CYP3A4. Concomitant use of EKTERLY with a strong CYP3A4 inhibitor increases sebetralstat exposure, which may increase the risk of sebetralstat adverse reactions.

**Please see additional Important Safety Information throughout.
Please see full Prescribing Information.**

INDICATION

EKTERLY® (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

IMPORTANT SAFETY INFORMATION

Adverse reactions: The most commonly reported adverse reaction was headache.

Drug interactions: EKTERLY is a substrate of CYP3A4. Concomitant use of EKTERLY with a strong CYP3A4 inhibitor increases sebetralstat exposure, which may increase the risk of sebetralstat adverse reactions. Avoid use of EKTERLY with strong CYP3A4 inhibitors and reduce the dose of EKTERLY to one dose of 300 mg (one tablet) with moderate CYP3A4 inhibitors. Concomitant use may decrease efficacy. The use of EKTERLY with strong or moderate CYP3A4 inducers is not recommended.

Use in specific populations: Avoid use of EKTERLY in patients with severe hepatic impairment (Child-Pugh Class C). The recommended dosage of EKTERLY is one dose of 300 mg (one tablet) in patients with moderate hepatic impairment (Child-Pugh Class B).

There are no available data on EKTERLY in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are no data on the presence of sebetralstat or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production.

The safety and effectiveness of EKTERLY in pediatric patients aged under 12 years of age have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact KalVista Pharmaceuticals, Inc. at **1-855-258-4782** or FDA at **1-800-FDA-1088** or www.fda.gov/medwatch.

Please see full accompanying **Prescribing Information**.

References: **1.** EKTERLY. Package insert. KalVista Pharmaceuticals, Inc.; 2025. **2.** KalVista Pharmaceuticals announces FDA approval of EKTERLY (sebetralstat), first and only oral on demand treatment for hereditary angioedema. Published July 2025. Accessed July 2025. **3.** Riedl MA, Farkas H, Aygören-Pürsün E, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks. *N Engl J Med.* 2024;391(1):32-43. doi:10.1056/NEJMoa2314192 **4.** Data on File. KalVista Pharmaceuticals, Inc. 2024. **5.** Riedl MA, Farkas H, Aygören-Pürsün E, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks. *N Engl J Med.* 2024;391(1)(suppl 1):1-33. doi:10.1056/NEJMoa2314192 **6.** Bernstein JA, Aygören-Pürsün E, Cancian M, et al. Sebetralstat for on-demand treatment of mucosal hereditary angioedema attacks in KONFIDENT-S. *Clin Transl Allergy.* 2025;15(11):e70118. doi:10.1002/ctt2.70118